| 영문 | beta human chorionic gonadotropin | 한글 | 베타 사람융모성 생식샘자극호르몬 |
|---|---|---|---|
| 설명 | 태반세포에서 만들어지는 호르몬. 기능은 임신의 초기에 황체(원래 난자를 싸고 있던 세포들이 배란이 일어나서 난자가 빠져나간 후 주머니 모양을 이룬 것. 임신초기에 임신의 유지에 필요한 호르몬을 생성한다)의 유지에 기여하고, 태아의 고환조직에서 남성호르몬이 분비되는 것을 촉진시킨다. 또 이것은 임신초기의 임산부의 소변에서 많은 양이 검출되므로 이것을 이용해서 임신의 여부를 손쉽게 조사할 수가 있다. |
||
| 영문 | antiglobulin antibody | 한글 | 항글로불린항체 |
|---|---|---|---|
| 설명 | 항체에 대한 항체, 즉 특정 항체와 결합할 수 있는 항체. 대개 인간의 항체를 쥐에 주사하여 쥐로 하여금 인간 항체에 대한 항체를 만들게 한다(쥐에 있어서는 인간의 항체도 외부에서 들어온 물질이므로). 이것은 여러 가지 실험에서 인간의 특정항체를 검출하는데 이용한다. |
||
| 영문 | antibody | 한글 | 항체 |
|---|---|---|---|
| 설명 | 사람의 몸에서 면역에 관계하는 물질. 외부에서 들어온 물질과 꼭 맞게 결합을 하여서 그 물질의 생물학적 활동을 억제하거나 파괴하거나 사람의 다른 면역세포로 하여금 공격하기 용이하게 해주는 기능을 가지고 있다. 항체는 면역글로부린이라는 것으로 이루어져 있고 그 형태에 따라 IgA, IgE, IgG, IgD등으로 나눈다. |
||
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
|---|---|
| AMLS | antimouse lymphocyte serum |
| FALG | fowl antimouse lymphocyte globulin |
| RAMT | rabbit antimouse thymocyte |
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
| RAMBS | Rabbit antimouse brain serum |
|---|---|
| HAMA | Human anti-mouse antibody |
| HAMA | Human anti-murine antibody |
| HuMAb | Human monoclonal antibody |
| hMAb | Human monoclonal antibody |
| affinity antibody | The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible. (05 Mar 2000) |
|---|---|
| agglutinating antibody | 1. An antibody that causes clumping or agglutination of the bacteria or other cells which either stimulated the formation of the agglutinin, or contain immunologically similar, reactive antigen. Synonym: agglutinating antibody, immune agglutinin. 2. A substance, other than a specific agglutinating antibody, that causes organic particles to agglutinate, commonly qualified, e.g., plant agglutinin. (05 Mar 2000) |
| anaphylactic antibody | Antibody that has an affinity for certain kinds of cells, in addition to and unrelated to its specific affinity for the antigen that induced it, because of the properties of the Fc portion of the heavy chain. See: heterocytotropic antibody, homocytotropic antibody, cytotropic antibody test. Synonym: anaphylactic antibody, cytophilic antibody. (05 Mar 2000) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| antibody | An immunoglobulin molecule that has a specific amino acid sequence by virtue of which it interacts only with the antigen that induced its synthesis in cells of the lymphoid series (especially plasma cells) or with antigen closely related to it. Antibodies are classified according to their ode of action as agglutinins, bacteriolysins, haemolysins, opsonins, precipitins, etc. (18 Nov 1997) |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| antibody-dependent enhancement | Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors. (12 Dec 1998) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| antibody diversity | The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|